Cardiovascular Health GLP1 has been shown to reduce the risk of major adverse cardiovascular events, such as heart attack and stroke, in individuals with type 2 diabetes and high cardiovascular risk
doi: 10.1111/dom.14179 106 RileyDREssaHAustinPPrestonFKargboIIbarburuGHet al
Emerging research on semaglutide and MS Perhaps the most exciting development for MS patients considering Wegovy is emerging evidence that semaglutide may have neuroprotective benefits beyond weight loss
There is a concrete two-part study (Part 1 on human subjects and Part 2 on animals) that shows that chromium picolinate (CrPic) can control your food intake by reducing the appetite thus supporting weight reduction
Stimulation of new cell regeneration
Some individuals may have problems producing this protein due to genetics, age, chronic gastritis, autoimmune conditions, or bariatric surgery